Etiology and impact of cytomegalovirus disease on solid organ transplant recipients

被引:0
|
作者
McDevitt, Lisa M.
机构
[1] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA
[2] Tufts Univ New England Med Ctr, Boston, MA USA
关键词
antivirals; cytomegalovirus ifections; immunosuppressive agents; transplantation;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. The characteristics, etiology, natural history, and direct and indirect effects of CMV disease in solid organ transplant recipients are described. Summary. CMV is a common herpesvirus that may be present in the donor or recipient of a solid organ transplant. Even though it is rarely pathogenic in healthy patients, transplant recipients are at risk for CMV viremia and symptomatic disease due to their immune-suppressed status. In addition to symptoms directly attributed to active disease, CMV can have a variety of indirect effects. Indirect effects may include additional infectious complications, posttransplant lymphoproliferative disease, allograft rejection, allograft loss, or death. The three most prevalent risk factors for CMV infection are seronegativity in a recipient of an organ from a CMV-seropositive donor, the type of organ transplanted, and the degree of immune suppression. CMV prophylaxis is effective at preventing disease, but may result in a delayed onset where CMV disease occurs once the prophylaxis is stopped. Conclusion. Knowledge of risk factors for CMV infection and disease, the natural history in transplant recipients, and its direct and indirect effects will help clinicians make appropriate decisions regarding the use of preventive strategies.
引用
收藏
页码:S3 / S9
页数:7
相关论文
共 50 条
  • [1] Etiology and impact of cytomegalovirus disease on solid organ transplant recipients
    McDevitt, Lisa M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 : S3 - S9
  • [2] Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients
    Singh, N
    Wagener, MM
    ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) : 456 - 457
  • [3] Cytomegalovirus in Solid Organ Transplant Recipients
    Humar, A.
    Snydman, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : S78 - S86
  • [4] RECURRENT CYTOMEGALOVIRUS DISEASE IN SOLID-ORGAN TRANSPLANT RECIPIENTS
    FALAGAS, ME
    SNYDMAN, DR
    TRANSPLANTATION PROCEEDINGS, 1995, 27 (05) : 34 - 37
  • [5] Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients
    Len, Oscar
    Gavalda, Joan
    Aguado, Jose Maria
    Borrell, Nuria
    Cervera, Carlos
    Cisneros, Jose Miguel
    Cuervas-Mons, Valentin
    Gurgui, Merce
    Martin-Davila, Pilar
    Montejo, Miguel
    Munoz, Patricia
    Bou, German
    Carratala, Jordi
    Torre-Cisneros, Julian
    Pahissa, Albert
    CLINICAL INFECTIOUS DISEASES, 2008, 46 (01) : 20 - 27
  • [6] Impact of standardized protocols for cytomegalovirus disease prevention in pediatric solid organ transplant recipients
    Ganapathi, Lakshmi
    Blumenthal, Jennifer
    Alawdah, Laila
    Lewis, Lynne
    Gilarde, Jennifer
    Jones, Sarah
    Milliren, Carly
    Kim, Heung Bae
    Sharma, Tanvi S.
    PEDIATRIC TRANSPLANTATION, 2019, 23 (07)
  • [7] Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients - Response
    Kalil, AC
    Stoner, J
    ANNALS OF INTERNAL MEDICINE, 2006, 144 (06) : 457 - 457
  • [8] Cytomegalovirus infections in solid organ transplant recipients
    Timurkaynak, F.
    Azap, O. Kurt
    Arslan, H.
    Kursun, E.
    Demirhan, B.
    Haberal, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2006, 10 : S12 - S13
  • [9] Cytomegalovirus infection in solid organ transplant recipients
    Lumbreras, C.
    Manuel, O.
    Len, O.
    ten Berge, I. J. M.
    Sgarabotto, D.
    Hirsch, H. H.
    CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 : 19 - 26
  • [10] Cytomegalovirus prophylaxis in solid organ transplant recipients
    Patel, R
    Snydman, DR
    Rubin, RH
    Ho, M
    Pescovitz, M
    Martin, M
    Paya, CV
    TRANSPLANTATION, 1996, 61 (09) : 1279 - 1289